Business · India Bureau
Aurobindo Pharma poised for growth on respiratory launches, CDMO expansion
The pharmaceutical manufacturer is positioned to benefit from new respiratory product launches, expansion of its contract development and manufacturing operations, and strength in its US and European markets. Analysts view the company's valuation as attractive relative to projected earnings.
LSN India ·
Aurobindo Pharma is well-positioned to capitalise on several growth catalysts in the coming years, with its core US and European operations providing a stable foundation for expansion. The company's pipeline of respiratory product launches is expected to drive incremental revenue, while its contract development and manufacturing organisation (CDMO) segment represents a significant growth opportunity as the demand for outsourced pharmaceutical manufacturing continues to rise globally.
The company's established presence in regulated markets, particularly the United States and Europe, has enabled it to build strong relationships with customers and maintain competitive pricing power. These markets remain the primary revenue drivers and are expected to sustain growth momentum through new product introductions and market share gains.
Aurobindo's CDMO business is positioned to benefit from the broader industry trend of pharmaceutical companies outsourcing manufacturing operations. This segment offers higher margins and recurring revenue potential compared to traditional generic drug manufacturing, providing a strategic avenue for diversification and growth.
From a valuation perspective, the stock is trading at approximately 16 times estimated earnings for fiscal year 2028, a level that analysts suggest reflects reasonable pricing given the company's growth prospects and operational scale. This valuation metric positions the company competitively within the pharmaceutical sector and suggests potential upside for investors willing to take a longer-term view of the company's development trajectory.